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Malignant hyperthermia (MH) is a rare but life-threatening condition that is more frequently encountered and discussed within
the anesthesia literature. Here we through a case speciﬁcally discuss the susceptibility of individuals and/or families with asymp-
tomatic unexplained elevations of creatine kinase (CK), also frequently referred to as hyperCKemia or idiopathic hyperCKemia
(IHCK) in recent reports. The clinical implications would be to underscore the importance of this as a susceptibility to developing
MH and highlight the importance of genetic susceptibility testing in such cases. Anesthesiologists and critical care intensivists as
wellasprimarycarephysiciansshouldkeepthisinmindwhenseeingpatientswithasymptomatichyperCKemiaandpotentiallyin-
form them about the possibility of developing MH if exposed to triggering agents. Genetic susceptibility testing should be consid-
ered if available and family members should also receive nontriggering agents when undergoing anesthesia and wear Medic Alert
tags.
1.Introduction
Malignant hyperthermia (MH) is a rare but life-threatening
condition that is more frequently encountered and discussed
within the anesthesia literature [1]. Here we through a case
speciﬁcally discuss the susceptibility of individuals and/or
families with asymptomatic unexplained elevations of crea-
tine kinase (CK) or creatine phosphokinase (CPK), also fre-
quently referred to as HyperCKemia or idiopathic hyperCK-
emia (IHCK) in recent reports [2]. The clinical implications
would be underscoring the importance of this as a suscepti-
bility to developing MH. Anesthesiologists and critical care
intensivists as well as primary care physicians should keep
this in mind when seeing patients with asymptomatic hyper-
CKemia and potentially inform them about the possibility of
developing MH if exposed to triggering agents.
2. Case Presentation
An 18-year-old man with past medical history signiﬁcant
only for asymptomatic creatine phosphokinase (CPK) ele-
vation (familial) was transferred to our medical intensive
care unit after developing malignant hyperthermia (MH) in-
traoperatively at an outside hospital.
History of his presenting illness revealed that the patient
was in his usual state of health till a day prior to admission
when he got injured at a local high school football game. He
was noted to have a right tibia-ﬁbula fracture and underwent
IM nailing (rodding) of the right tibia by orthopedics.
Review of his operative records revealed that early in the
course of his surgery, it was noted that patient’s end tidal car-
bon dioxide concentration (ETCO2) was noted to have in-
creased from 42 to 100mmHg during the course of the sur-
gery and his temperature went up to >104 (apparently was
not measureable) following which concern was raised for
malignant hyperthermia (MH).
Labs were consistent for acidosis (pH 7.29) and hyper-
kalemia(K+-7mMol/L).PatientwasgivendantroleneIV(re-
commended initial dose being 2.5mg/kg) immediately along
with calcium gluconate, kayexalate, insulin/dextrose 50%
and albuterol as well for the hyperkalemia and transferred to
our facility for further management and care. Cooling blan-
kets, ﬂuids, and acetaminophen were also concomitantly ad-
ministered to bring his temperature down.2 Case Reports in Medicine
Table 1: Summary of 2 studies speciﬁcally studying the susceptibility of developing MH in patients with unexplained hyperCKemia.
Study Sample size Testing Outcome
(1) Malandrini et al. [3]
37
(i) 51.1% were asymptomatic
(ii) 26 males and 11 females
In vitro contracture testing with
halothane-caﬀeine
1MH susceptible (2.7%) and 1MH
equivocal patient
No familial cases noted in this study
(2) Weglinski et al. [2]
49
(i) All were asymptomatic
(ii) 36 males and 13 females
In vitro contracture testing with
halothane-caﬀeine
24 (49%) had positive contracture tests
14 patients had a family history of high
CK levels
Dantrolene (1mg/kg) IV was continued till hyperther-
mia resolved and was then transitioned to dantrolene PO
6mg/kg in 4 divided doses for the next 3 days. CPK levels
peaked up to 3922IU/L initially when the patient had pre-
sented and subsequently decreased during the course of his
stay.
In terms of medications charted at the outside hospi-
tal, patient got sevoﬂurane, propofol, lidocaine, labetalol,
rocuronium, fentanyl, and versed. It was presumed that this
would have been likely secondary to sevoﬂurane (one of the
volatile gaseous inhalation anesthetics which is a known trig-
ger to MH in susceptible individuals) [4–6].
Once we were able to talk to the family, it revealed a very
interesting family history. Apparently patient’s father was
noted to have CPK elevations after being started on a statin,
but these levels remained elevated despite the discontinu-
ation of the medication. It was at that point in time that
the patient’s primary care physician was concerned for a
possible familial elevation and screened his family too, which
also revealed high CPK levels. The highest CPK level of the
patient’s father has been up to 1600IU/L. Patient’s CPK level
has been in the range of 500–600(IU/L) and sisters’ levels
have been up to 1100IU/L. No family history of malignant
hyperthermia in the family or any history of any adverse
reactions to medications was reported. Patient’s family was
extensively worked up for known genetic mutations to
explain the high CPK levels along with screening for dystro-
phies and myopathies, but the results were inconclusive.
The signiﬁcance of this in the context of susceptibility to
MH is discussed as follows.
3.HyperCKemiaandSusceptibilityto
Malignant Hyperthermia
High creatine phosphokinase (CPK) levels usually signify
underlying myopathies or muscle injury [3]. However, in
some cases the cause is not identiﬁed and these patients con-
tinue to have asymptomatic elevations of the enzyme. This
is referred to as idiopathic hyperCKemia (IHCK) and classi-
callyisdeﬁnedby“atleast3serumCKlevelsmorethantwice
normal that remain increased over at least 3 months in pa-
tients with no evidence of neuromuscular disease” [2]. The
condition is noted more often in males and appears to be
familial (see Table 1) .Ah i g hp e r c e n t a g eo fa u t o s o m a ld o m i -
nant cases have also been reported [7].
Reviewing the literature, it is interesting to note that
these patients have been shown to be susceptible to develop-
ing malignant hyperthermia. Usually this is determined by
in vitro contracture testing, which is considered the gold
standard for assessing malignant hyperthermia susceptibility
(MHS) [8].
Table 1 outlines the outcomes of 2 studies speciﬁ-
cally assessing the susceptibility to malignant hyperthermia
(MHS) in IHCK. As evident, the incidence is noted to vary
widely and may also depend on the selection of cases selected
for testing. However, it is important to note that the test is
not 100% sensitive in ruling out susceptibility to developing
MH; thus, the true incidence of developing MH in patients
with idiopathic hyperCKemia is not known [3].
At the same time it is argued by some reports that it
is questionable if patients with asymptomatic elevations of
CPK should undergo MH susceptibility testing especially
if they do not have a family history of anesthesia-related
complications, given the incidence is variable and sometimes
can also lead to false positives [3]. However, in our opinion
withthefactthattheconditioncanbelifethreatening,andas
seen in our case as well, patient not having a family history of
any anesthesia-related complications, we would recommend
susceptibility testing if available.
We sent our patient’s blood work for testing at UPMC
laboratories and the sequence analysis identiﬁed a heterozy-
gous nucleotide substitution of C to T at nucleotide 487
[c.487C > T] in exon 6 of the RYR1 gene (type 1 ryanodine
receptor gene, a gene for calcium channel of skeletal muscle
which is located on chromosome 19q13.1). The change in-
volves the 1st nucleotide of codon 163 and results in a mis-
sense amino acid variant: [p.Arg163Cys] that is known to
cause the disease. Per laboratory data here, it is estimated
that more than 50% of the malignant hyperthermia cases are
located in regions where many of the reported mutations are
clustered.
Furthermore, in this day and age with numerous other
alternatives available from anesthesia standpoint, it would
not be reasonable to take the risk of exposing patients to
triggering agents even if the risk is small. Table 2 summarizes
some of the known triggering agents for MH along with clas-
ses of drugs that have been questionably linked to MH.
As advocated by some authors, we would also recom-
mend that family members receive nontriggering agents
whenundergoinganesthesiaandwearMedicAlerttags[2,9].
The establishment of registries to keep track of such rare
disorders and conduct research would be helpful in not only
providing diagnostic testing but also in further elucidat-
ing the pathogenetic mechanisms responsible for the life-
threatening complications seen [10].Case Reports in Medicine 3
Table 2: Groups of drugs noted to cause or associated with malignant hyperthermia [10, 11].
Inhaled general anesthetics Depolarizing muscle relaxants Other classes of drugs that show inconclusive
evidence/case reports [12]
Sevoﬂurane∗∗ Succinylcholine Serotonergic drugs
Desﬂurane Statins
Enﬂurane Ondansetron
Chloroform Methylene blue
(Trichloromethane, methyl trichloride) Phosphodiesterase III inhibitors
Cyclopropane Tetracaine
Ether
Halothane
Isoﬂurane
Methoxyﬂurane
Trichloroethylene
Xenon
∗∗Trigger in our patient.
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